Laurus Labs (NSE:LAURUSLABS, BOM:540222) has received board approval to invest 833 million Indian rupees in the company's joint venture company KRKA Pharma, according to a Thursday filing to the Indian stock exchanges.
The company's joint venture partner KRKA d.d., Novo mesto, Slovenia will also invest 867 million rupees in KRKA.
Both joint venture partners will maintain their shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs.
The investment is expected to be completed by March 31.
The additional investment will be used by KRKA Pharma to acquire land and to meet the initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market.
Shares of the company were up over 1% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。